Application of heated inlet extensions to the TSI 3306/3321 system: Comparison with the Andersen cascade impactor and next generation impactor

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 4, 2006, Pages 543-554

  Myrdal, Paul B ^a   Mogalian, Erik ^a   Mitchell, Jolyon ^b   Nagel, Mark ^b   Wright, Charlie ^c   Kiser, Brent ^c   Prell, Mark ^c   Woessner, Mike ^c   Stein, Stephen W ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b TRUDELL MEDICAL INTERNATIONAL   (Canada)

^c TSI INCORPORATED   (United States)

^d 3M COMPANY   (United States)

Author keywords

Andersen cascade impactor; Impactor inlet; MDI; Metered dose inhaler; Next generation impactor

Indexed keywords

ALCOHOL; BECLOMETASONE DIPROPIONATE; NORFLURANE;

AEROSOL; AIR TEMPERATURE; ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DEVICE; DRUG FORMULATION; EVAPORATION; HEATING; METERED DOSE INHALER; PARTICLE SIZE; SPECTROMETER; TEMPERATURE;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; EQUIPMENT DESIGN; METERED DOSE INHALERS; PARTICLE SIZE; PHARYNX; TEMPERATURE;

EID: 33846074001     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.543     Document Type: Article

References (18)

1. USP 28-NF 23. Suppl. 1. 2005. Chapter 601-physical tests and determinations: aerosols. United States Pharmacopeia, Rockville, MD, 3298-3316.
2. European Pharmacopeia. Suppl. 5.1. 2005. Section 2.9.18-preparations for inhalation: aerodynamic assessment of fine particles. European Pharmacopeia, 5th ed. Council of Europe, Strasbourg, France, 2799-2811.
3. U.S. Food and Drug Administration. 1998. Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products: chemistry, manufacturing and controls documentation-draft guidance for industry. Center for Drug Evaluation and Research, Rockville, MD, docket 98D-0997.
4. Guideline on the pharmaceutical quality of inhaled and nasal products. Committee for Medicinal Products for Human Use (CHMP). EMEA/CHMP/QWP/49313/205- Final. London, UK. [Also published as: Health Canada 2005. Guideline on the pharmaceutical quality of inhaled and nasal products. Health Products and Food Branch. File 06-106624-547. Ottawa, Canada.]
5. Mitchell, J.P., and M.W. Nagel. 2003. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol Med. 16:341-377.
6. International Standards Organization (ISO). 1999. Particle size analysis-laser diffraction methods: Part 1: General principles. ISO Geneva, Switzerland, 13320-13321.
7. Heyder, J., and M.U. Svartengren. 2002. Basic principles of particle behavior in the human respiratory tract. In H. Bisgaard, C. O'Callaghan and G.C. Smaldone, eds. Drug Delivery to the Lung. Marcel Dekker, New York, 21-45.
8. Mitchell, J.P., and M.W. Nagel. Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols. 1999. J. Aerosol Med. 12:217-240.
9. TSI Inc. 2005. Product Information: Model 3306 Impactor Inlet. TSI Inc., St. Paul, MN.
10. Mitchell, J.P., M.W. Nagel, K.J. Wiersema, et al. 2003. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, Next Generation Pharmaceutical Impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer. AAPS Pharm. Sci. Technol. 4:article 54.
11. Myrdal, P.B., S.W. Stein, E. Mogalian, et al. 2004. Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: solution metered dose inhalers. Drug Dev. Ind. Pharm. 30:859-868.
12. Kamiya, A., M. Sakagami, M. Hindle, et al. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and their USP methods. 2004. J. Pharm. Sci. 93:1828-1836.
13. Mogalian, E., and P.B. Myrdal. 2005. Application of USP inlet extensions to the TSI Impactor System 3306/3320 using HFA 227 based metered dose inhalers. Drug Dev. Ind. Pharm. 31:977-985.
14. Leach, C. 1996. Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. In R.N. Balby, P.R. Byron, and S.J. Farr, eds. Respiratory Drug Delivery V. Interpharm Press, Buffalo Grove, IL, 133-144.
15. Dalby, R.N., and Byron, P.R. 1988. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm. Res. 5:36-39.
16. Stein, S.W., and J.S. Stefely. Reinventing metered dose inhalers: from poorly efficient CFC MDIs to highly efficient HFA MDIs. Drug Deliv. Technol. 3:46-51.
17. Stein, S.W., and P.B. Myrdal. 2004. A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J. Pharm. Sci. 93:2158-2175.
18. Stein, S.W., and B.J. Gabrio. 2000. Understanding throat deposition during cascade impactor testing. In R.N. Dalby, P.R. Byron, Farr, S.J. et al., eds. Respiratory Drug Delivery VII. Serentec Press, Raleigh, NC, 287-290.